Loading...
Relapse rates in patients with multiple sclerosis treated with fingolimod: subgroup analyses of pooled data from three phase 3 trials
BACKGROUND: Fingolimod is a once-daily, orally administered therapy for relapsing forms of MS. It has been shown to reduce relapse rates significantly in all phase II and phase III clinical trials when compared with placebo and intramuscular interferon β-1a (IFNβ-1a IM). METHODS: This study compared...
Na minha lista:
| Udgivet i: | Mult Scler Relat Disord |
|---|---|
| Main Authors: | , , , , |
| Format: | Artigo |
| Sprog: | Inglês |
| Udgivet: |
2016
|
| Fag: | |
| Online adgang: | https://ncbi.nlm.nih.gov/pmc/articles/PMC4985567/ https://ncbi.nlm.nih.gov/pubmed/27456887 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1016/j.msard.2016.05.015 |
| Tags: |
Tilføj Tag
Ingen Tags, Vær først til at tagge denne postø!
|